반응식
[Cl:1][C:2]1[CH:3]=[N:4][CH:5]=[C:6]([Cl:27])[C:7]=1[CH2:8][C:9]([C:11]1[C:24]2[O:23][CH2:22][C:18]3([CH2:21][O:20][CH2:19]3)[CH2:17][O:16][C:15]=2[C:14]([O:25][CH3:26])=[CH:13][CH:12]=1)=[O:10].[OH:28]O>C(Cl)Cl.C[Re](=O)(=O)=O.O=[Mn]=O>[Cl:27][C:6]1[CH:5]=[N+:4]([O-:28])[CH:3]=[C:2]([Cl:1])[C:7]=1[CH2:8][C:9]([C:11]1[C:24]2[O:23][CH2:22][C:18]3([CH2:21][O:20][CH2:19]3)[CH2:17][O:16][C:15]=2[C:14]([O:25][CH3:26])=[CH:13][CH:12]=1)=[O:10]참가 물질
6
반응물 2
생성물 1
시약·촉매·용매 3
실험 절차
To a solution of 2-(3,5-Dichloropyridin-4-yl)-1-{9-methoxy-spiro[2H-1,5-benzodioxepin-3(4H),3′-oxetane]-6-yl}ethanone [121] (20.5 mg, 50 μmol) in CH2Cl2 (1 mL) was added 30% H2O2 (15 μL) and methyltrioxorhenium(VII) (5 mg). The mixture was stirred for 18 h, added MnO2 (5 mg) and was stirred for another hour. CH2Cl2 (10 mL) was added and the organic phase was washed with water. The combined organic phase was dried over MgSO4 and evaporated to dryness under reduced pressure. Standard HPLC purification afforded 14 mg of the product.
후처리
- stirringwas stirred for another hour
- washthe organic phase was washed with water
- dry with materialThe combined organic phase was dried over MgSO4
- customevaporated to dryness under reduced pressure
- customStandard HPLC purification
출처 및 근거
- ORD 기록
- ord-0eb6c5e22bcb453e93177ccfb4df0523
- 출처 데이터셋
- uspto-grants-2012_12
- 특허 번호
- US08338431B2
연결된 노트
불러오는 중…